Zobrazeno 1 - 10
of 96
pro vyhledávání: '"D. R. Mould"'
CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19
Autor:
E. V. Tavlueva, E. V. Zernova, M. P. Kutepova, N. E. Kostina, V. S. Lesina, D. R. Mould, K. Ito, A. V. Zinchenko, A. N. Dolgorukova, M. V. Nikolskaya, M. S. Lemak, O. V. Filon, M. Yu. Samsonov
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 10, Iss 5, Pp 460-471 (2022)
The aim of the article is to study pharmacokinetic characteristics of intravenous olokizumab in patients with moderate COVID-19 to relieve a hyperinflammation syndrome.Materials and methods. The pharmacokinetic study was conducted as a part of a phas
Externí odkaz:
https://doaj.org/article/96b8864adb544463a121630b4d6598a5
Publikováno v:
Journal of Crohn's and Colitis. 15:S362-S363
Background Recent studies suggest pediatric Crohn’s Disease (CD) patients have higher infliximab clearance (IFX CL) for body weight and lower serum IFX when dosing by weight. Our aim was to determine if IFX CL calculated based on therapeutic drug m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5f41d927bc7f022c8fbb6c9db3664ed
https://doi.org/10.1093/ecco-jcc/jjab076.461
https://doi.org/10.1093/ecco-jcc/jjab076.461
Publikováno v:
Clinical pharmacology and therapeutics. 99(4):405-418
Dashboard systems for clinical decision support integrate data from multiple sources. These systems, the newest in a long line of dose calculators and other decision support tools, utilize Bayesian approaches to fully individualize dosing using infor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3c0497ca7795c84d57f3ff244afcfad
https://doi.org/10.1002/cpt.334
https://doi.org/10.1002/cpt.334
Autor:
G H Huynh, Hien Q. Huynh, C Prosser, Diane Tomalty, Anne M. Griffiths, A Petrova, Matthew W Carroll, D R Mould, Jennifer deBruyn, Wael El-Matary, C Kluthe, Eytan Wine
Publikováno v:
Journal of Crohn's and Colitis. 13:S064-S064
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbbb0582c2ae66d905ff8b5885853f39
https://doi.org/10.1093/ecco-jcc/jjy222.092
https://doi.org/10.1093/ecco-jcc/jjy222.092
Autor:
D R Mould
Publikováno v:
Clinical Pharmacology & Therapeutics. 92:125-131
Disease-progression models are useful tools in drug development. They increase the information obtained from clinical trials, improve study designs, and allow in silico evaluations of new treatment combinations and dose regimens. Disease-progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0225e8405f4d272a5cc230786834661
https://doi.org/10.1038/clpt.2012.53
https://doi.org/10.1038/clpt.2012.53
Autor:
S. Reif, J. Kuhlmann, P. Hillmen, D. R. Mould, M. J. Keating, Peter L. Bonate, L. R. Brettman, Steven D. Weitman, A. Baumann
Publikováno v:
British Journal of Clinical Pharmacology. 64:278-291
What is already known about this subject • The pharmacokinetics of alemtuzumab have been incompletely described to date. • At most, presentations of half-life have been reported in clinical articles using data at the individual level. What this p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b94f24ddfc5c0844f76d70a198a2130a
https://doi.org/10.1111/j.1365-2125.2007.02914.x
https://doi.org/10.1111/j.1365-2125.2007.02914.x
Autor:
D R Mould
Publikováno v:
Clinical pharmacology and therapeutics. 92(3)
Modeling during drug development is routinely used to integrate subject-level information, evaluate response, and inform clinical trials. Model-based meta-analysis (MBMA) combines aggregate safety and efficacy results from many trials. Because MBMA i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55d2ce63f343ac107957b2f6b1392543
https://pubmed.ncbi.nlm.nih.gov/22760002
https://pubmed.ncbi.nlm.nih.gov/22760002
Publikováno v:
Clinical pharmacology and therapeutics. 82(1)
Generally, information required for approval of new drugs is dichotomous in that the drug is either efficacious and safe or not. Consequently, the purpose of most confirmatory clinical trials is to test the null hypothesis. The primary reasons for de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78e14bd617cc79d27f898464efb2f31d
https://pubmed.ncbi.nlm.nih.gov/17507925
https://pubmed.ncbi.nlm.nih.gov/17507925
Publikováno v:
Clinical Pharmacology & Therapeutics. 73:P87-P87
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85a3b027302c3b9835bd834a332063e6
https://doi.org/10.1016/s0009-9236(03)90678-3
https://doi.org/10.1016/s0009-9236(03)90678-3
Publikováno v:
Clinical Pharmacology & Therapeutics. 73:P25-P25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87a0473fb0e463e8bd86f86c89ddf92d
https://doi.org/10.1016/s0009-9236(03)90445-0
https://doi.org/10.1016/s0009-9236(03)90445-0